Mitochondria Inhibitors
1 drugsAbout Mitochondria
Mitochondria are essential organelles responsible for energy production (ATP) through oxidative phosphorylation, impacting cellular functions like apoptosis and calcium signaling.
Mitochondria are emerging as drug targets, particularly in cardiovascular disease, due to their central role in cellular metabolism; however, there is currently no genetic evidence directly linking them to specific diseases.
Currently, one FDA-approved drug, MYOVIEW, targets mitochondria and is a small molecule; MEDI-PHYSICS is the only company with an approved drug in this space.
Top Mitochondria Drugs
MEDI-PHYSICS is the only company with an approved drug targeting mitochondria.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's validation.
Mitochondria Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Mitochondria, using small molecule modality.
Explore alternative modalities like peptides or gene therapies to differentiate from existing approaches.
Mitochondria Clinical Trials 3 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Mitochondria. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Mitochondria Drug Approval Timeline (1996 - 1996)
The first and only drug, MYOVIEW, was approved in 1996.
The lack of recent approvals indicates potential challenges or a lack of interest in targeting mitochondria, requiring careful evaluation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Mitochondria. A trial counts if an approved drug acting on Mitochondria is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.